April 8, 2020
A prospective “PARP inhibitor” drug that has struggled to show effectiveness in clinical trials against cancers can be structurally modified to greatly increase its power to kill tumor cells, researchers from Penn Medicine report in Science. The team also showed that PARP inhibitor compounds can be “tuned” in the opposite […]
